BICO Group Archives - Medical Design Sourcing

BICO’s Scienion and Cellenion launch SpheroOne large-particle sorter and dispenser

The SpheroOne large-particle sorter and dispenser (Photo courtesy of BICO Group]

BICO Group subsidiaries Scienion and Cellenion today announced the launch of their SpheroOne single large-particle sorter and dispenser for drug testing using complex in-vitro 3D models.

The SpheroOne platform can dispense individual spheroids, organoids and tumoroids, handling cellular aggregates ranging from 80 µm to 600 µm and complementing Cellenion’s CellenOne platform for sorting and dispensing single cells (ranging from 0.5 µm to 80 µm), the companies said in a news release.

“Current offerings suffer from low throughput, inconsistent sorting and intensive manual dispensing,” Cellenion founder and Managing Director Guilhem Tourniaire said in the news release. “SpheroOne is going to play a significant role toward replacing animal models in pre-clinical research as it allows automated sorting, enables development of h…

BICO’s Scienion and Cellenion Launch SpheroOne large-particle sorter and dispenser

The SpheroOne large-particle sorter and dispenser (Photo courtesy of BICO Group]

BICO Group subsidiaries Scienion and Cellenion today announced the launch of their SpheroOne single large-particle sorter and dispenser for drug testing using complex in-vitro 3D models.

The SpheroOne platform can dispense individual spheroids, organoids and tumoroids, handling cellular aggregates ranging from 80 µm to 600 µm and complementing Cellenion’s CellenOne platform for sorting and dispensing single cells (ranging from 0.5 µm to 80 µm), the companies said in a news release.

“Current offerings suffer from low throughput, inconsistent sorting and intensive manual dispensing,” Cellenion founder and Managing Director Guilhem Tourniaire said in the news release. “SpheroOne is going to play a significant role toward replacing animal models in pre-clinical research as it allows automated sorting, enables development of …

BICO’s Cytena launches C.Station automated cell line development platform for antibody and gene therapies

Cytena’s C.Station platform [Photo courtesy of Cytena]

BICO Group subsidiary Cytena today announced the launch of its C.Station platform for automating the development of stable cell lines.

Cytena said in a news release that C.Station is a user-friendly platform that covers the entire cell line development workflow, from single-cell cloning of transfected cells to the selection of high-producing clones and upscaling.

Cytena CEO Dr. Julian Riba called it “a key step in advancing the Bio Convergence revolution by combining several proven technologies, cell cultures, and smart software to produce monoclonal antibodies and viral vectors for gene therapy.”

Cytena patented its single-cell dispensing technology in 2014 as a spin-off from the University of Freiburg in Germany. Like BICO’s name (an abbreviation of “bio convergence”), Cytena’s name is a combination of the Latin…

BICO plans to acquire QInstruments for its bioautomation business

Erik Gatenholm is the CEO of BICO Group. [Photo courtesy of BICO]BICO Group has a deal to acquire QInstruments for $71 million, the life sciences holding company said Friday.

Headquartered in Jena, Germany, QInstruments was founded by CEO Olaf Simmat and Christian Stange in 2003. It’s a developer, manufacturer and supplier of advanced sample preparation automation for clinical diagnostics and biomedical and life science research.

Get the full story at our sister site Medical Design & Outsourcing.

BICO plans to acquire QInstruments for its bioautomation business

Erik Gatenholm is the CEO of BICO Group. [Photo courtesy of BICO]

BICO Group has a deal to acquire QInstruments for $71 million, the life sciences holding company said Friday.

Headquartered in Jena, Germany, QInstruments was founded by CEO Olaf Simmat and Christian Stange in 2003. It’s a developer, manufacturer and supplier of advanced sample preparation automation for clinical diagnostics and biomedical and life science research.

BICO plans to close the deal “as soon as reasonably possible,” according to a news release. QInstruments will operate as a standalone company in BICO’s bioautomation business area to strengthen BICO’s ability to improve workflows for its other subsidiaries and customers.

“Our team invents user-friendly and intuitive systems that enable multidisciplinary research in a cost and time efficient manner,” Simmat said in the news release. “With BICO, we share a common vision o…